Sandra Horning, MD
Combining frontline atezolizumab (Tecentriq) with chemotherapy improved overall survival (OS) and progression-free survival (PFS) compared with chemotherapy alone in patients with extensive-stage small cell lung cancer (ES-SCLC), meeting the coprimary endpoints of the phase III IMpower133 trial.
Genentech also announced in May 2018 that in the phase III IMpower130 study, adding atezolizumab to nab-paclitaxel and carboplatin in the frontline setting significantly improved OS in patients with advanced nonsquamous non–small cell lung cancer. The company plans to share the study data at an upcoming oncology meeting.
- Jotte RM, Cappuzzo F, Vynnychenko I, et al. IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. J Clin Oncol. 2018;36 (suppl; abstr LBA9000).
- Socinski MA, Jotte R, Cappuzzo F, et al. Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC. J Clin Oncol. 2018;36 (suppl; abstr 9002).
... to read the full story